Product Highlight - WEZLANA

The First FDA-Approved Interchangeable Biosimilar for Psoriasis and Psoriatic Arthritis

• Established interchangeability¹

• Demonstrated clinical comparability^2,3

• Large-scale evidence^4,5

• Comparable safety profile^2,3

References:
1. Hicks, L. FDA approves first ustekinumab biosimilar. Medscape. 1 November 2023. Available at: https://www.medscape.com/viewarticle/997961?form=fpf. Accessed 11 July 2025.
2. Wezlana^® Hong Kong Prescribing Information. January 2025.
3. Data on file, Amgen, 2022.
4. US National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04761627. Updated January 11, 2024. Accessed 20 May 2025.
5. US National Library of Medicine. Available at: https://clinicaltrials.gov/study/NCT04607980. Updated December 12, 2024. Accessed 20 May 2025.

Please read the full prescribing information prior to administration. For medical inquiries or to report adverse events/product complaints, please contact 800 961 142 or email medinfo.JAPAC@amgen.com. For Healthcare Professionals Only.

Wezlana^® is a registered trademark owned or licensed by Amgen Inc., its subsidiaries, or affiliates.